Publications

Battaglin F, O'Neil BH, Stintzing S, Ou FS, Zemla TJ, Niedzwiecki D, Innocenti F, Hochster HS, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Lerchenmüller C, Weiss L, Heinrich K, Goldberg RM, Mayer RJ, Schilsky RL, Blanke CD, Venook AP, Lenz HJ, Heinemann V. Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European journal of cancer (Oxford, England : 1990). 2025. PMID: 40803104

Williams BM, Mulima G, Kaimila B, Marapese KD, Salima AW, Evans A, Ngwira N, Kajombo C, Gallaher J, Charles A, McGinty K, Buckle G, Mody GN. Esophageal Cancer Staging in Malawi: The Feasibility of Chest Radiography and Abdominal Ultrasound for Initial Evaluation. Research square. 2025. PMID: 40799736

Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 40769277

Tolani MA, Agbo CA, Umar SS, Paciorek A, Ojewola RW, Mohammed F, Maiga M, Kaninjing E, Ahmed M, DeBoer R. An intervention mapping approach to the development and evaluation of a community-based prostate cancer early detection programme in Nigeria. PLOS global public health. 2025. PMID: 40763189

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney S, Treister NS, Matthews C, Johnson M. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2025. PMID: 40762824

Kosibaty Z, Luck C, Okimoto RA. The CIC::DUX4 oncoprotein maintains DNA integrity through direct regulation of the catalytic subunit of DNA polymerase epsilon (POLE). Oncogene. 2025. PMID: 40760094

Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning. Medical physics. 2025. PMID: 40903915

Roy S, Ozay ZI, Guha A, Sun Y, Chi KN, Morgan SC, Malone S, Wallis CJD, Brown JR, Barata PC, Kishan AU, Jia AY, Zaorsky NG, Swami U, Chowdhury S, Small EJ, Spratt DE, Saad F, Agarwal N. Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials. JAMA network open. 2025. PMID: 40833694

Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, Smith KL, Wolff AC, Melisko ME, Shinn EH, Gallagher K, Angove R, Wheeler SB, Rocque GB. Understanding Associations Between Patient-Level Factors and Participation in a Breast Cancer Clinical Trial. Cancer medicine. 2025. PMID: 40836443

Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood. 2025. PMID: 40749169

Iagaru A, Suarez JF, Behr S, Aggarwal R, Paredes P, Buffi N, Penhoat T, Ceci F, Walz J, Doumerc N, Coulanges M, Xu Z, Seigne C, Wilke C, Catafau AM, Fanti S, Maurer T, GuideView study investigators. Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473463

Le C, Lewis M, Harris CS, Berger L, Chavez-Iglesias E, Morse L, Sucher A, Roy R, Olshen A, Hammer MJ, Paul S, Wallhagen M, Chan R, Sayer M, Yom S, Cho NW, Chan A, Levine J, Dhruva A, Miaskowski C, Conley YP, Kober KM. A Data-Driven Epigenetic Characterization of Morning Fatigue Severity in Oncology Patients Receiving Chemotherapy: Associations With Epigenetic Age Acceleration, Blood Cell Types, and Expression-Associated Methylation. Cancer medicine. 2025. PMID: 40709591

Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, Duch J, Perdigo MS, Mainta IC, Bonnefoy PB, Coulanges M, Tang J, Seigne C, Wilke C, Catafau AM, Iagaru A, Aggarwal R. Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473464

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025. PMID: 40753466

Beresis R, Prathigudupu V, Cable C, Yu A, Adler M, Ramamoorthi R, Yeon SK, Gordan JD, Sharma S, DeGrado WF, Zaro B, Chen JY, Jo H. Exploration of a Class of Aryl Imidazolyl Ureas As Potent Acid Ceramidase Inhibitors for the Treatment of Fibrotic Diseases. ACS omega. 2025. PMID: 40821548

Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB. Correction: Chen et al. Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes. Cancers 2025, 17, 2211. Cancers. 2025. PMID: 40805300

Hawes MR, Chakravarty D, Cheng J, Handley MA, Tsoh JY, Lin TK, Hiatt RA, Vijayaraghavan M. The Healthy Homes Study: Protocol for a cluster randomized trial of a place-based smoke-free home intervention in affordable housing. PloS one. 2025. PMID: 40729126

Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet (London, England). 2025. PMID: 40744051

Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40711480

Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. Journal for immunotherapy of cancer. 2025. PMID: 40713179